PE20090150A1 - Compuestos derivados de oxadiazol - Google Patents
Compuestos derivados de oxadiazolInfo
- Publication number
- PE20090150A1 PE20090150A1 PE2008000672A PE2008000672A PE20090150A1 PE 20090150 A1 PE20090150 A1 PE 20090150A1 PE 2008000672 A PE2008000672 A PE 2008000672A PE 2008000672 A PE2008000672 A PE 2008000672A PE 20090150 A1 PE20090150 A1 PE 20090150A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- oxadiazol
- methylethyl
- chloro
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title 1
- -1 OXADIAZOLE DERIVATIVE COMPOUNDS Chemical class 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE OXADIAZOL DE FORMULA I, EN EL QUE R5 Y R6 ES H O R2 Y EL OTRO ES (a); UNO DE R3 Y R4 ES (b); A ES UN FENILO O UN ANILLO HETEROARILO DE 5 O 6 MIEMBROS; R1 ES H O REPRESENTA HASTA 3 SUSTITUYENTES SELECCIONADOS DE ALQUILO(C1-C4), CICLOALQUILO(C5-C7), TRIFLUOROMETOXI, ENTRE OTROS; R2 ES H O REPRESENTA HASTA 3 SUSTITUYENTES SELECCIONADOS DE H, ALQUILO(C1-C4), CIANO, ENTRE OTROS; R7 ES H O HALOGENO; Z ES ALQUILO(C1-C4). SON SELECCIONADOS ACIDO 3-[5-(5-{3-CLORO-4-[(1-METILETIL)OXI]FENIL}-1,2,4-OXADIAZOL-3-IL)-1H-INDAZOL-1-IL]PROPANOICO, ACIDO 4-[4-(5-{5-CLORO-6-[(1-METILETIL)OXI]-3-PIRIDINIL}-1,2,4-OXADIAZOL-3-IL)-1H-INDAZOL-1-IL]-2,2-DIMETILBUTANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR S1P1 Y SON UTILES EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE, TRASPLANTES, NEUROPATIAS INFLAMATORIAS, DIABETES, METASTASIS TUMORAL, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0707617A GB0707617D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
| GB0805993A GB0805993D0 (en) | 2008-04-02 | 2008-04-02 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090150A1 true PE20090150A1 (es) | 2009-05-08 |
Family
ID=39604751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000672A PE20090150A1 (es) | 2007-04-19 | 2008-04-17 | Compuestos derivados de oxadiazol |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8324254B2 (es) |
| EP (1) | EP2137181B1 (es) |
| JP (1) | JP5313229B2 (es) |
| KR (1) | KR20090130062A (es) |
| AR (1) | AR066095A1 (es) |
| AT (1) | ATE500252T1 (es) |
| AU (1) | AU2008240773B2 (es) |
| BR (1) | BRPI0809472A2 (es) |
| CA (1) | CA2684385A1 (es) |
| CL (1) | CL2008001099A1 (es) |
| CO (1) | CO6321136A2 (es) |
| CR (1) | CR11119A (es) |
| DE (1) | DE602008005285D1 (es) |
| DO (1) | DOP2009000237A (es) |
| EA (1) | EA016443B1 (es) |
| IL (1) | IL200870A (es) |
| JO (1) | JO2686B1 (es) |
| MA (1) | MA31311B1 (es) |
| MX (1) | MX2009011155A (es) |
| MY (1) | MY146606A (es) |
| NZ (1) | NZ579595A (es) |
| PE (1) | PE20090150A1 (es) |
| TW (1) | TWI408137B (es) |
| WO (1) | WO2008128951A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007236707C1 (en) | 2006-04-03 | 2012-05-24 | Astellas Pharma Inc. | Hetero compound |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| JP2011506600A (ja) * | 2007-12-18 | 2011-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 自己免疫性障害および炎症性障害の治療において有用なテトラヒドロシクロペンタ［ｂ］インドール−３−イルカルボン酸誘導体 |
| AR070986A1 (es) * | 2008-04-04 | 2010-05-19 | Lilly Co Eli | Compuesto de 3-indazoil-4 -piridilisotiazoles, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para tratar la ansiedad |
| GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| PT2307007E (pt) * | 2008-07-23 | 2014-11-13 | Novartis Ag | Moduladores do receptor esfingosina 1 fosfato e sua utilização para tratamento de inflamação muscular |
| US8653131B2 (en) | 2008-08-22 | 2014-02-18 | Baxter Healthcare S.A. | Polymeric benzyl carbonate-derivatives |
| CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| EA201170828A1 (ru) * | 2008-12-18 | 2011-12-30 | Мерк Сероно С.А. | Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза |
| GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2513095A4 (en) * | 2009-12-18 | 2013-05-15 | Glaxo Group Ltd | OXADIAZOLSUBSTITUTED INDAZONE DERIVATIVES FOR USE AS SPHINGOSIN-1-PHOSPHATE-1 (S1P1) RECEPTOR AGONISTS |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| WO2013113915A1 (en) | 2012-02-03 | 2013-08-08 | Novartis Ag | Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester |
| JP2016028016A (ja) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
| KR20160043948A (ko) | 2013-08-20 | 2016-04-22 | 메이지 세이카 파루마 가부시키가이샤 | S1p1 수용체 아고니스트의 평가방법 및 스크리닝 방법 |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| CN109100971B (zh) * | 2018-08-20 | 2024-02-09 | 合肥华耀电子工业有限公司 | 一种带互锁功能的开关机时序控制电路 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939238A1 (de) * | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
| DE4002466A1 (de) | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
| US5262416A (en) * | 1990-01-28 | 1993-11-16 | Bayer Aktiengesellschaft | Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters |
| US5462943A (en) * | 1990-01-28 | 1995-10-31 | Bayer Aktiengesellschaft | Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides |
| US5523312A (en) * | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2001199983A (ja) * | 2000-01-18 | 2001-07-24 | Teijin Ltd | ベンズイミダゾール誘導体 |
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| EP1622866B1 (en) * | 2003-04-30 | 2012-07-25 | Novartis AG | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| WO2004103279A2 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| EP1670463A2 (en) * | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| CN1894225A (zh) | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| CN101043887A (zh) | 2004-10-22 | 2007-09-26 | 默克公司 | 用作s1p受体激动剂的2－(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物 |
| KR101377790B1 (ko) * | 2005-02-25 | 2014-03-27 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 화합물 및 이의 용도 |
| DE602006003642D1 (en) * | 2005-03-23 | 2008-12-24 | Actelion Pharmaceuticals Ltd | Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten |
| CA2605594A1 (en) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| RU2008110949A (ru) * | 2005-08-23 | 2009-09-27 | Айрм Ллк (Bm) | Соединения и композиции-иммуносупрессанты |
| GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| AU2007236707C1 (en) * | 2006-04-03 | 2012-05-24 | Astellas Pharma Inc. | Hetero compound |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
-
2008
- 2008-04-17 US US12/596,488 patent/US8324254B2/en not_active Expired - Fee Related
- 2008-04-17 AR ARP080101584A patent/AR066095A1/es not_active Application Discontinuation
- 2008-04-17 MX MX2009011155A patent/MX2009011155A/es active IP Right Grant
- 2008-04-17 BR BRPI0809472-1A patent/BRPI0809472A2/pt not_active IP Right Cessation
- 2008-04-17 JO JO2008183A patent/JO2686B1/en active
- 2008-04-17 CL CL200801099A patent/CL2008001099A1/es unknown
- 2008-04-17 PE PE2008000672A patent/PE20090150A1/es not_active Application Discontinuation
- 2008-04-17 JP JP2010503494A patent/JP5313229B2/ja not_active Expired - Fee Related
- 2008-04-17 EP EP08736315A patent/EP2137181B1/en not_active Not-in-force
- 2008-04-17 AT AT08736315T patent/ATE500252T1/de not_active IP Right Cessation
- 2008-04-17 TW TW097113880A patent/TWI408137B/zh not_active IP Right Cessation
- 2008-04-17 CA CA002684385A patent/CA2684385A1/en not_active Abandoned
- 2008-04-17 NZ NZ579595A patent/NZ579595A/en not_active IP Right Cessation
- 2008-04-17 MY MYPI20094368A patent/MY146606A/en unknown
- 2008-04-17 AU AU2008240773A patent/AU2008240773B2/en not_active Expired - Fee Related
- 2008-04-17 KR KR1020097021613A patent/KR20090130062A/ko not_active Ceased
- 2008-04-17 EA EA200970967A patent/EA016443B1/ru not_active IP Right Cessation
- 2008-04-17 DE DE602008005285T patent/DE602008005285D1/de active Active
- 2008-04-17 WO PCT/EP2008/054647 patent/WO2008128951A1/en not_active Ceased
-
2009
- 2009-09-10 IL IL200870A patent/IL200870A/en not_active IP Right Cessation
- 2009-10-08 DO DO2009000237A patent/DOP2009000237A/es unknown
- 2009-10-15 MA MA32280A patent/MA31311B1/fr unknown
- 2009-10-16 CO CO09115828A patent/CO6321136A2/es active IP Right Grant
- 2009-11-19 CR CR11119A patent/CR11119A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ579595A (en) | 2012-06-29 |
| EA200970967A1 (ru) | 2010-02-26 |
| KR20090130062A (ko) | 2009-12-17 |
| US8324254B2 (en) | 2012-12-04 |
| ATE500252T1 (de) | 2011-03-15 |
| JP2010524886A (ja) | 2010-07-22 |
| TWI408137B (zh) | 2013-09-11 |
| MX2009011155A (es) | 2009-10-30 |
| EP2137181A1 (en) | 2009-12-30 |
| EP2137181B1 (en) | 2011-03-02 |
| WO2008128951A1 (en) | 2008-10-30 |
| CR11119A (es) | 2010-01-18 |
| IL200870A0 (en) | 2010-05-17 |
| DOP2009000237A (es) | 2010-05-31 |
| CA2684385A1 (en) | 2008-10-30 |
| AU2008240773A1 (en) | 2008-10-30 |
| DE602008005285D1 (de) | 2011-04-14 |
| IL200870A (en) | 2013-08-29 |
| AR066095A1 (es) | 2009-07-22 |
| JP5313229B2 (ja) | 2013-10-09 |
| CL2008001099A1 (es) | 2008-10-24 |
| US20100113528A1 (en) | 2010-05-06 |
| EA016443B1 (ru) | 2012-05-30 |
| BRPI0809472A2 (pt) | 2014-09-09 |
| AU2008240773B2 (en) | 2013-10-03 |
| MY146606A (en) | 2012-09-14 |
| JO2686B1 (en) | 2013-03-03 |
| TW200911794A (en) | 2009-03-16 |
| MA31311B1 (fr) | 2010-04-01 |
| HK1138001A1 (en) | 2010-08-13 |
| CO6321136A2 (es) | 2011-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090150A1 (es) | Compuestos derivados de oxadiazol | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20081398A1 (es) | Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1) | |
| PE20110906A1 (es) | Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif | |
| PE20081532A1 (es) | Compuestos novedosos | |
| PE20081199A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20081467A1 (es) | Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk) | |
| PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PE20080895A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
| CO6260017A2 (es) | Compuestos de oxazol, oxadiazol y tiadiazol utiles para el control de nematodos | |
| PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
| PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
| PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| PE20091816A1 (es) | Inhibidores de bace | |
| PE20080927A1 (es) | Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk) | |
| RU2009120882A (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20040649A1 (es) | Procedimiento para la preparacion de benzoilureas heterociclicamente sustituidas | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| PE20041016A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| PE20080405A1 (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb | |
| PE20120657A1 (es) | Compuesto para el tratamiento de trastornos metabolicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |